Makers Laboratories Ltd
Incorporated in 1984, Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. [1]
- Market Cap ₹ 97.3 Cr.
- Current Price ₹ 165
- High / Low ₹ 184 / 105
- Stock P/E 29.5
- Book Value ₹ 98.8
- Dividend Yield 0.00 %
- ROCE -7.84 %
- ROE -12.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 36.4 days to 21.2 days
Cons
- The company has delivered a poor sales growth of 0.95% over past five years.
- Company has a low return on equity of -8.25% over last 3 years.
- Earnings include an other income of Rs.10.6 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
61.55 | 68.37 | 64.91 | 61.41 | 58.13 | 55.95 | 46.60 | 51.31 | 44.34 | 52.34 | 42.46 | 48.85 | 46.41 | |
57.66 | 65.93 | 60.53 | 56.71 | 52.69 | 51.28 | 44.38 | 48.55 | 41.03 | 49.24 | 46.60 | 52.60 | 48.09 | |
Operating Profit | 3.89 | 2.44 | 4.38 | 4.70 | 5.44 | 4.67 | 2.22 | 2.76 | 3.31 | 3.10 | -4.14 | -3.75 | -1.68 |
OPM % | 6.32% | 3.57% | 6.75% | 7.65% | 9.36% | 8.35% | 4.76% | 5.38% | 7.47% | 5.92% | -9.75% | -7.68% | -3.62% |
1.57 | 0.21 | 0.94 | 0.41 | 1.24 | 1.50 | 2.56 | 0.18 | 0.41 | 0.80 | 1.14 | 1.14 | 10.60 | |
Interest | 0.96 | 0.49 | 0.39 | 0.36 | 0.27 | 0.36 | 0.26 | 0.70 | 1.60 | 1.68 | 1.38 | 1.63 | 1.60 |
Depreciation | 1.01 | 0.97 | 1.53 | 1.25 | 1.08 | 1.57 | 1.50 | 1.99 | 4.20 | 1.91 | 2.40 | 2.71 | 2.78 |
Profit before tax | 3.49 | 1.19 | 3.40 | 3.50 | 5.33 | 4.24 | 3.02 | 0.25 | -2.08 | 0.31 | -6.78 | -6.95 | 4.54 |
Tax % | 30.09% | 50.42% | 30.88% | 34.29% | 30.77% | 27.83% | 18.87% | 148.00% | -22.12% | 45.16% | -6.05% | 0.00% | |
2.44 | 0.60 | 2.35 | 2.31 | 3.70 | 3.06 | 2.45 | -0.12 | -1.62 | 0.17 | -6.36 | -6.95 | 3.30 | |
EPS in Rs | 4.14 | 1.02 | 3.98 | 3.92 | 6.27 | 5.19 | 4.15 | -0.20 | -2.75 | 0.29 | -10.78 | -11.78 | 5.60 |
Dividend Payout % | 0.00% | 0.00% | 20.94% | 21.30% | 13.30% | 16.08% | 20.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -3% |
5 Years: | 1% |
3 Years: | 3% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 148% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 32% |
3 Years: | -7% |
1 Year: | 47% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | -6% |
3 Years: | -8% |
Last Year: | -13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 4.92 | 5.90 | 5.90 | 5.90 |
Reserves | 17.39 | 17.99 | 19.71 | 21.42 | 29.15 | 31.90 | 36.78 | 39.70 | 44.70 | 45.38 | 52.38 | 45.55 | 52.39 |
4.40 | 2.12 | 0.80 | 0.18 | 1.43 | 1.29 | 6.38 | 13.05 | 15.99 | 19.40 | 11.20 | 15.37 | 3.96 | |
12.04 | 15.99 | 13.67 | 13.68 | 14.70 | 15.18 | 11.94 | 16.20 | 13.51 | 15.78 | 15.30 | 19.33 | 13.00 | |
Total Liabilities | 38.75 | 41.02 | 39.10 | 40.20 | 50.20 | 53.29 | 60.02 | 73.87 | 79.12 | 85.48 | 84.78 | 86.15 | 75.25 |
12.26 | 11.94 | 11.47 | 10.39 | 17.30 | 16.62 | 18.10 | 32.89 | 30.59 | 29.94 | 40.45 | 39.88 | 31.83 | |
CWIP | 0.01 | 1.92 | 2.71 | 4.23 | 0.15 | 0.11 | 6.42 | 0.69 | 0.12 | 8.94 | 0.04 | 0.00 | 0.10 |
Investments | 4.04 | 2.50 | 2.35 | 2.35 | 7.12 | 9.18 | 11.16 | 15.04 | 23.66 | 22.55 | 22.52 | 22.56 | 22.59 |
22.44 | 24.66 | 22.57 | 23.23 | 25.63 | 27.38 | 24.34 | 25.25 | 24.75 | 24.05 | 21.77 | 23.71 | 20.73 | |
Total Assets | 38.75 | 41.02 | 39.10 | 40.20 | 50.20 | 53.29 | 60.02 | 73.87 | 79.12 | 85.48 | 84.78 | 86.15 | 75.25 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.01 | 1.30 | 1.32 | 3.52 | 5.53 | 0.21 | 5.39 | 4.23 | 0.67 | 6.80 | -1.42 | -3.06 | |
0.81 | -1.12 | -1.00 | -1.49 | -2.96 | -2.06 | -8.31 | -8.43 | -2.65 | -8.78 | -3.55 | -2.04 | |
-1.85 | -0.45 | -0.38 | -0.91 | 0.39 | -1.09 | 3.92 | 2.91 | 1.37 | 1.77 | 4.94 | 5.12 | |
Net Cash Flow | -0.03 | -0.27 | -0.06 | 1.12 | 2.96 | -2.95 | 1.00 | -1.29 | -0.61 | -0.21 | -0.04 | 0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 58.59 | 66.89 | 66.58 | 85.65 | 75.73 | 73.20 | 39.32 | 53.71 | 59.19 | 37.31 | 64.73 | 49.09 |
Inventory Days | 100.40 | 82.37 | 83.67 | 60.14 | 84.04 | 135.66 | 147.65 | 132.22 | 176.97 | 159.36 | 109.67 | 135.03 |
Days Payable | 90.69 | 86.93 | 68.30 | 73.93 | 75.31 | 67.88 | 49.81 | 90.79 | 98.48 | 52.16 | 61.39 | 127.16 |
Cash Conversion Cycle | 68.31 | 62.33 | 81.96 | 71.87 | 84.46 | 140.97 | 137.16 | 95.14 | 137.68 | 144.51 | 113.01 | 56.96 |
Working Capital Days | 65.77 | 65.93 | 71.53 | 71.92 | 44.77 | 79.33 | 72.61 | 44.67 | 82.73 | 43.59 | 44.53 | 21.15 |
ROCE % | 12.82% | 7.81% | 13.08% | 15.63% | 15.54% | 13.15% | 7.63% | 1.80% | -1.05% | 3.02% | -7.77% | -7.84% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
6 Nov - Issuance of duplicate share certificates to shareholder.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Oct
- Standalone And Consolidated Q2H1FY25 Results 29 Oct
-
Board Meeting Outcome for Standalone And Consolidated Q2H1FY25 Results
29 Oct - Standalone and consolidated unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30Th September, 2024.
17 Oct - Board meeting to discuss Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio
The Co’s product portfolio covers a wide range of General Health Therapeutic segments. Its top formulation brands are Duramol (Paracetamol), Artemak-AB (a-ß Arteether), Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). [1]